show files
File 155:MEDLINE R 19[illegible]-[illegible] Aug W1
File 5:Biosis Previews R 19[illegible]-[illegible] Aug W1
[illegible] 2002 BIOSIS
File 315:ChemEng & Biotec Abs 19[illegible]-[illegible] Jun
[illegible] 2002 DECHEMA
File 73:EMBASE 1974-2002 Aug W1
[illegible] 2[illegible] Elsevier Science B.V.
File [illegible]:CA SEARCH R 19[illegible]-[illegible] UD=1[illegible]
[illegible] 2[illegible] AMERICAN CHEMICAL SOCIETY
?ds

Set	Items	Description
S1	55	AU=WOUTERS S? OR AU=WOUTERS, S?
S2	127	AU=RENGGLI H? OR AU=RENGGLI, H?
S3	57	AU=HORBACH D. OR AU=HORBACH, [illegible]
S4	[illegible]	ANTIBOD? OR IMMUNOGLOBULIN? [illegible]
S5	17[illegible]44	EPITOPE? ?
S6	[illegible]	HAPTEN? ?
S7	[illegible]	BIND? OR BOUND
S8	[illegible]	UNBIND? OR UNBOUND
S9	27[illegible]406	DISSOCIAT?
S10	[illegible]	COMPLEX
S11	[illegible]	PH
S12	[illegible]	(ION OR IONIC) (3N) STRENGTH? ?
S13	15[illegible]61	OSMOLARITY
S14	4[illegible]5	FAB
S15	922548	PATHOGEN?
S16	7768	PORPHYROMONAS
S17	290367	ACIDI?
S18	11654	BASICI?
S19	25694	ALKALINI?
S20	54	(S1-S3) AND S4
S21	4	S20 AND S11
S22	0	S20 AND (S12 OR S13)
S23	4	RD S21 (unique items)
S24	2[illegible]41	S4 AND (S5 OR S6) (5N) (S7-S10)
S25	[illegible]5729	(S7-S10) (5N) (S11-S1[illegible])
S26	31627	PHYSIOLOGY(3N)PH AND S25
S27	34[illegible]	S25 NOT S26
S28	[illegible]97	S27 AND S4 AND (S5 OR S6)
S29	[illegible]	(S7-S10) (5N) (S12-S1[illegible])
S30	56	S29 AND (S5 OR S6)
S31	[illegible]12	S28 OR S30
S32	1[illegible]	S31 AND S15
S33	4	RD S32 (unique items
S34	[illegible]4	S31 AND (BACTERI? OR VIRUS? OR MICROB? OR FUNGUS OR FUNGI OR YEAST? ?)
S35	[illegible]	RD S34 (unique items
S36	[illegible]	S25 AND S16
S37	17	RD S36 (unique items
S38	[illegible]	S37 NOT S26
S39	4[illegible]	S23 OR S33 OR S35 OR S38
S40	[illegible]	S14 AND (S7-S1[illegible])
S41	4[illegible]	S40 AND (S11-S13)
S42	[illegible]	PHYSIOLOGY (3N) PH AND S41
S43	[illegible]	S41 NOT S42

S44 41 S43 AND (S1? OR BACTERI? OR VIRU? OR MICROB? OR FUNGU? OR FUNGI OR YEAST? [illegible])
S45 [illegible] S44 AND S4
S46 14 RD S45 (unique items)
S47 [illegible] S3? AND S4
S48 [illegible] S46 OR S47
S49 [illegible] S1? [illegible] S4 OR S5
S50 [illegible] S49 AND [illegible]
S51 [illegible] [illegible] AND [illegible]
S52 [illegible] [illegible]
S53 [illegible] S4? OR [illegible]
?t 53/7/all

53/7/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13286670 21645154 PMID: 11767875

Dual binding capabilities of anti-double-stranded DNA antibodies and anti-ribosomal phosphoprotein P antibodies.

Takeda I; Rayno K; Movafagh F B; Wolfson-Reichlin M; Reichlin M

Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma University Health Sciences Center, Oklahoma City, USA.

Lupus (England) 2001, 10 (12) p847-?, ISSN 0961-2033

Journal Code: [illegible]

Contract/Grant No.: R01 AR43975; AR; NIAMS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The aim of this study is to identify distinctive properties of pathogenic anti-double stranded DNA antibodies and anti-ribosomal P antibodies . The binding activity of anti-dsDNA and anti-ribosomal P antibodies to their cognate antigens in 0.15 M and 1.5 M NaCl solutions on ELISA was examined. All anti-dsDNA and anti-ribosomal P antibodies exhibited a loss of their binding activity from 37.5 to 100 and from 2.3 to 97.4 in high ionic strength buffers, respectively. In contrast, anti-U1RNP antibodies and anti-Ro/SSA antibodies lost from [illegible] to [illegible].7 and from 0 to 40.1 of their binding activity, respectively. Anti-dsDNA and anti-ribosomal P antibodies from patients with nephropathy showed significantly higher binding activity in high ionic strength buffers than those from patients without nephropathy. Study of paired sera from lupus nephritis patients revealed that anti-dsDNA and anti-ribosomal P antibodies from patients during disease flare show stronger binding activity in high ionic strength buffer than those during remission. Most anti-dsDNA and anti-ribosomal P antibodies bind their antigens by ionic interactions that are sensitive to high salt. Such dual binding capability of anti-dsDNA and anti-ribosomal P antibodies may underlie their multiple cross reactivities to various epitopes and help elucidate the pathogenic potential of autoantibody subsets.

Record Date Created: 20020111

53/7/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13116?6? 21652374 PMID: 1143760?

Rapid two-step purification of a recombinant mouse Fab fragment expressed